Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

CTI BioPharma Corp. (CTIC)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
Visitors trend2W10W9M
4.8700+0.4400 (+9.93%)
At close: 04:00PM EDT
4.8700 0.00 (0.00%)
After hours: 04:06PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
Previous Close4.4300
Open4.4800
Bid4.8400 x 1800
Ask4.8500 x 3000
Day's Range4.4300 - 4.8950
52 Week Range1.4300 - 5.7600
Volume2,945,215
Avg. Volume6,381,586
Market Cap470.892M
Beta (5Y Monthly)1.11
PE Ratio (TTM)N/A
EPS (TTM)-0.9020
Earnings DateMar 15, 2022 - Mar 21, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.53
  • Motley Fool

    Why CTI Biopharma Stock Is Surging Today

    Shares of CTI BioPharma (NASDAQ: CTIC) moved sharply higher after the drugmaker reported first-quarter results Friday morning. Investors were pleased with the initial sales figures for Vonjo, its first approved drug, and pushed the stock price 20.8% higher as of 11:22 a.m. ET. On March 1, 2022, the FDA approved Vonjo to treat patients with myelofibrosis, a rare bone marrow disorder.

  • Zacks

    CTI BioPharma (CTIC) Reports Q1 Loss, Tops Revenue Estimates

    CTI BioPharma (CTIC) delivered earnings and revenue surprises of -5.71% and 6.74%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

  • PR Newswire

    CTI BioPharma Reports First Quarter 2022 Financial Results

    CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the first quarter ended March 31, 2022.

Advertisement
Advertisement